Company Filing History:
Years Active: 2018
Title: Chih-Tsung Chang: Innovator in Cancer Treatment
Introduction
Chih-Tsung Chang is a notable inventor based in Menlo Park, California. He has made significant contributions to the field of pharmaceuticals, particularly in the development of cancer treatment options. His innovative work focuses on the inhibition of specific kinases that play a crucial role in tumor growth and metastasis.
Latest Patents
Chih-Tsung Chang holds a patent for MAP4K4 (HGK) inhibitors. This invention provides mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) inhibitors, along with pharmaceutically acceptable salts, hydrides, and stereoisomers thereof. The compounds developed are utilized in pharmaceutical compositions and methods for treating individuals in need. These methods include administering an effective amount of the compound or composition to detect a resultant reduction in tumor cell growth, cancer, or metastasis.
Career Highlights
Chih-Tsung Chang is associated with SRI International, a renowned research institute known for its innovative contributions to various scientific fields. His work at SRI International has allowed him to focus on groundbreaking research that has the potential to impact cancer treatment significantly.
Collaborations
Chih-Tsung Chang has collaborated with talented individuals such as Ling Jong and Jaehyeon Park. These collaborations have fostered an environment of innovation and creativity, leading to advancements in their respective fields.
Conclusion
Chih-Tsung Chang's contributions to the development of MAP4K4 inhibitors represent a significant advancement in cancer treatment. His work continues to inspire and pave the way for future innovations in the pharmaceutical industry.